ArticleClinical and translational medicine2013
Treatment of hepatitis C virus infection in the future.
Article in Clinical and translational medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 30 citations in OpenAlex.
- Insight into the drug resistance mechanisms of GS-9669 caused by mutations of HCV NS5B polymerase via molecular simulation.Computational and structural biotechnology journal · 2021Article
- Hepatitis C virus genotypes in Myanmar.World journal of gastroenterology · 2016Article
- Does Hepatitis C Treatment Adherence Affect Risk of Liver Transplantation? A Historical Cohort Study.Journal of managed care & specialty pharmacy · 2016Observational
- Structure-activity relationship studies on quinoxalin-2(1H)-one derivatives containing thiazol-2-amine against hepatitis C virus leading to the discovery of BH6870.Molecular diversity · 2015Article
- Roles of lipoprotein receptors in the entry of hepatitis C virus.World journal of hepatology · 2015Review
- Is the use of IL28B genotype justified in the era of interferon-free treatments for hepatitis C?World journal of virology · 2015Article
- Current management of patients with hepatocellular carcinoma.World journal of hepatology · 2015Article
- Natural interferon-beta treatment for patients with chronic hepatitis C in Japan.World journal of hepatology · 2015Review
- Antiviral therapies for chronic hepatitis C virus infection with cirrhosis.World journal of hepatology · 2015Review
- Faldaprevir for the treatment of hepatitis C.International journal of molecular sciences · 2015Review
- Direct-acting Antiviral Agents for the Treatment of Chronic Hepatitis C Virus Infection.Journal of clinical and translational hepatology · 2014Review
- IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens.International journal of hepatology · 2014Article
- Automating crystallographic structure solution and refinement of protein-ligand complexes.Acta crystallographica. Section D, Biological crystallography · 2014Article
- Hepatitis C virus protease inhibitor-resistance mutations: our experience and review.World journal of gastroenterology · 2013Review
- IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase.World journal of hepatology · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Two direct-acting antivirals (DAAs) against hepatitis C virus (HCV): telaprevir and boceprevir, are now available in combination with peginterferon plus ribavirin for the treatment of chronic hepatitis C infection. Although these drugs are potent inhibitors of HCV replication, they occasionally result in severe adverse events. In the present clinical trials, in their stead, several second-generation DAAs are being investigated. Most of them are being viewed with high expectations, but they also require the combination with peginterferon plus ribavirin. In the near future, we might be using all-oral DAAs and interferon-free regimens for the treatment of HCV-infected patients, and these would be potent inhibitors of HCV and have less adverse events.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.